Open Access Open Access  Restricted Access Subscription Access

An Essential Parameters of Glucose Intolerance Include Etiology, Epidemiology, Patho Physiology, Diagnosis, Differential Diagnosis, Treatment and Enhancement of Health-Care Team Outcomes.

Muralinath E., Guruprasad M., Madhavi Latha C., Sheethal U., Vyshnavi J., Varsha V., Prathysha M.V.S., Karthik Jayanth. Y.

Abstract


Glucose intolerance (GI) is a metabolic condition that results in hyperglycaemia. It can be explained as dysglycemia that includes both prediabetes and diabetes. This activity shows the evaluation and management of glucose intolerance and explain about the role of the interprofessional team in promoting care for patients along with this condition.

An Essential Parameters of Glucose Intolerance Include Etiology, Epidemiology, Patho Physiology, Diagnosis, Differential Diagnosis, Treatment and Enhancement of Health-Care Team Outcomes.


Full Text:

PDF

References


American Diabetes Association. (2018). Classification and diagnosis of diabetes: Standards of medical care in diabetes—2018. Diabetes Care, 41(Suppl. 1), S13–S27.

Bansal, N. (2015). Prediabetes diagnosis and treatment: A review. World Journal of Diabetes, 6(2), 296–303. https://doi.org/10.4239/wjd.v6.i2.296

Ferrannini, E., Gastaldelli, A., & Iozzo, P. (2011). Pathophysiology of prediabetes. Medical Clinics of North America, 95(2), 327–339, vii–viii.

Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., Zinman, B., & American Diabetes Association. (2007). Impaired fasting glucose and impaired glucose tolerance: Implications for care. Diabetes Care, 30(3), 753–759.

Vikram, N. K., & Jialal, I. (2014). Use of HbA1c in the diagnosis of diabetes and prediabetes: Sensitivity versus specificity. Metabolic Syndrome and Related Disorders, 12(5), 255–257.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee; Goldenberg, R., & Punthakee, Z. (2013). Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Canadian Journal of Diabetes, 37(Suppl. 1), S8–S11.

Diabetes Canada Clinical Practice Guidelines Expert Committee; Punthakee, Z., Goldenberg, R., & Katz, P. (2018). Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Canadian Journal of Diabetes, 42(Suppl. 1), S10–S15.

Brannick, B., & Dagogo-Jack, S. (2018). Prediabetes and cardiovascular disease: Pathophysiology and interventions for prevention and risk reduction. Endocrinology and Metabolism Clinics of North America, 47(1), 33–50. https://doi.org/10.1016/j.ecl.2017.09.001

Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016). Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Reviews Endocrinology, 12(10), 566–592. https://doi.org/10.1038/nrendo.2016.91

Bailey, C. J., Aschner, P., Del Prato, S., LaSalle, J., Ji, L., Matthaei, S., & Global Partnership for Effective Diabetes Management. (2013). Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diabetes & Vascular Disease Research, 10(5), 397–409. https://doi.org/10.1177/1479164113492665

Ganesan, K., Rana, M. B. M., & Sultan, S. (2023). Oral hypoglycemic medications. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557694/


Refbacks

  • There are currently no refbacks.